Adtalem Global Education, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Adtalem Global Education, Inc. (ATGE)

If you purchased or acquired Adtalem Global Education securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Adtalem Global Education

Adtalem Global Education provides workforce solutions and educational services, focusing on healthcare and medical education.

The company operates institutions such as Chamberlain University and Walden University, which offer degree programs and professional certifications in nursing, healthcare, and related fields.

Potential Concerns Under Investigation

Attorneys are reviewing whether Adtalem Global Education and certain executives made false or misleading statements or failed to disclose material information between August 7, 2025, and October 30, 2025.

During this period, Adtalem indicated strong operating momentum and rising student demand. In fiscal 2025, the company reported 12.9% year-over-year revenue growth to $1.79 billion, citing higher enrollment at Chamberlain University (+5.8%) and Walden University (+15%) in the fourth quarter. These results allegedly helped push Adtalem’s stock to a 52-week high of about $154 in late September 2025.

On August 7, 2025, during the Q4 FY2025 earnings call, management told investors that the company saw no reduction in student demand and that regulatory changes to the Grad PLUS loan program were not expected to hinder enrollment.

Lawyers may investigate whether management was aware by October 2025 that demand was weakening in key programs, particularly at Chamberlain University, and that the elimination of Grad PLUS loans would pressure student funding.

On October 30, 2025, an analyst report stated that growth at Adtalem’s Chamberlain unit had slowed due to marketing execution issues. The report contradicted prior public optimism and seemingly represented the first external acknowledgment of these problems.

Following publication of the analyst report, Adtalem’s stock fell approximately 31%, dropping from $141.77 per share on October 30, 2025, to $98.02 at the close on October 31, 2025, causing significant losses to investors.

Lawyers are investigating whether Adtalem adequately disclosed enrollment trends, marketing challenges, and financing risks tied to the Grad PLUS phase-out before the stock decline.

Your Rights and Next Steps

This is an ongoing investigation and not a filed lawsuit. Investors who purchased or otherwise acquired Adtalem Global Education securities between August 7, 2025, and October 30, 2025, and suffered financial losses may have legal rights. If evidence shows that investors were misled, a class action may be filed to recover damages for affected shareholders.

Lawyers are available to help investors review their options and determine whether they qualify to participate. There is no cost or obligation to join the investigation, and participation is confidential.

You May Be Entitled to Compensation

Securities investigations are time-sensitive, and acting promptly can help preserve your rights. If you purchased or acquired Adtalem Global Education securities during the relevant period, you may be eligible to seek compensation for your losses.

To protect your rights and learn more about your options, complete the form below to join the investigation.